| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
| Targets |
H-Glu-Asp-OH does not have a specific biological target as a drug. It is a metabolite and a diagnostic marker for Gaucher disease. The compound is a dipeptide composed of two amino acids that are involved in various metabolic pathways. However, H-Glu-Asp-OH itself is not designed to interact with specific receptors or enzymes for therapeutic purposes. Its primary value is as a biomarker and a research tool for studying amino acid metabolism and disease diagnosis.
|
|---|---|
| ln Vitro |
In vitro, H-Glu-Asp-OH is used as a standard and a substrate in biochemical assays. It is used as a diagnostic marker for Gaucher disease, where elevated levels of this dipeptide are found in the blood of patients. The compound may be used in enzymatic assays to study the activity of peptidases that hydrolyze glutamyl-aspartyl bonds. It does not exhibit significant pharmacological activities such as receptor binding or enzyme inhibition. Its role in research is primarily as a metabolite and a diagnostic marker.
|
| ln Vivo |
H-Glu-Asp-OH is not a pharmacologically active compound and therefore does not have defined in vivo activity as a therapeutic agent. It is a metabolite that is present in the blood. Its levels are elevated in patients with Gaucher disease, and it can be used as a diagnostic marker. When administered to animals, it would likely be metabolized to release glutamic acid and aspartic acid. Its primary value is as a biomarker and a research tool for studying amino acid metabolism and disease.
|
| Enzyme Assay |
In vitro enzyme assays for H-Glu-Asp-OH are typically designed to study the activity of peptidases that hydrolyze glutamyl-aspartyl bonds. A standard protocol involves incubating the compound with an enzyme preparation in a suitable buffer. The hydrolysis of the dipeptide bond releases glutamic acid and aspartic acid, which can be quantified by HPLC or mass spectrometry. These assays are used to characterize the substrate specificity of these enzymes.
|
| Cell Assay |
In vitro cellular assays using H-Glu-Asp-OH are limited because the compound is primarily a metabolite. However, it can be used in cell culture studies to investigate amino acid metabolism. Cells are cultured in media supplemented with the compound, and its hydrolysis and the subsequent effects on cellular amino acid pools are monitored. These experiments can be conducted in cell lines to study the metabolism of glutamyl-aspartyl dipeptides.
|
| Animal Protocol |
In vivo animal studies with H-Glu-Asp-OH are not typically conducted for therapeutic purposes. However, it may be used in metabolic studies to investigate amino acid metabolism and disease. A typical protocol involves measuring the levels of H-Glu-Asp-OH in blood or tissues in disease models, such as Gaucher disease, to evaluate its utility as a diagnostic marker. These studies help to understand the metabolic changes associated with the disease.
|
| ADME/Pharmacokinetics |
As a small, hydrophilic dipeptide, H-Glu-Asp-OH is expected to be rapidly metabolized in the body. Its levels in blood are regulated by its production from protein metabolism and its degradation by peptidases. Detailed pharmacokinetic data are not typically reported, as the compound is primarily a biomarker rather than a drug candidate.
|
| Toxicity/Toxicokinetics |
H-Glu-Asp-OH is generally considered to have low toxicity, consistent with its status as an endogenous metabolite. It is a dipeptide composed of the amino acids glutamic acid and aspartic acid. Standard laboratory safety precautions, including the use of personal protective equipment, are recommended. No significant systemic toxicity is anticipated at typical research doses.
|
| Additional Infomation |
Glu-Asp is a dipeptide composed of L-glutamic acid and L-aspartic acid linked by peptide bonds. It is a metabolite functionally related to L-glutamic acid and L-aspartic acid. α-Glutamine-aspartic acid has been reported in Trypanosoma brucei, and relevant data are available.
H-Glu-Asp-OH (α-Glutamylaspartic acid, CAS 3918-84-1) is a dipeptide composed of L-glutamic acid and L-aspartic acid. Its molecular formula is C₉H₁₄N₂O₇ and its molecular weight is 262.22 g/mol. It is a metabolite that is present in the blood. Its levels are elevated in patients with Gaucher disease, and it can be used as a diagnostic marker. It is intended for research use only. |
| Molecular Formula |
C9H14N2O7
|
|---|---|
| Molecular Weight |
262.21666
|
| Exact Mass |
262.08
|
| CAS # |
3918-84-1
|
| PubChem CID |
99716
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.53g/cm3
|
| Boiling Point |
608.2ºC at 760mmHg
|
| Flash Point |
321.6ºC
|
| Index of Refraction |
1.561
|
| LogP |
-4.6
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
18
|
| Complexity |
355
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C(O)CC[C@H](N)C(N[C@H](C(O)=O)CC(O)=O)=O
|
| InChi Key |
FYYSIASRLDJUNP-WHFBIAKZSA-N
|
| InChi Code |
InChI=1S/C9H14N2O7/c10-4(1-2-6(12)13)8(16)11-5(9(17)18)3-7(14)15/h4-5H,1-3,10H2,(H,11,16)(H,12,13)(H,14,15)(H,17,18)/t4-,5-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-amino-4-carboxybutanoyl]amino]butanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8136 mL | 19.0680 mL | 38.1359 mL | |
| 5 mM | 0.7627 mL | 3.8136 mL | 7.6272 mL | |
| 10 mM | 0.3814 mL | 1.9068 mL | 3.8136 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
